Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Marc Phelan who wrote (1446)	3/20/2001 11:06:00 AM
From: Starlight	Read Replies (2) \| Respond to of 1605

According to the press release, those studies were to have been presented yesterday: -March 15, 2001--Vasomedical, Inc. (Nasdaq: VASO - news) announced today that four studies on the efficacy of EECP® enhanced external counterpulsation have been accepted for presentation at the 50th Annual Scientific Sessions of the American College of Cardiology (ACC), to be held in Orlando, Florida March 18-21, 2001. Among the four studies, two report on the long-term benefits of EECP therapy, one compares the effectiveness of EECP versus Percutaneous Coronary Interventions (PCI) such as balloon angioplasty and stent placement in treating patients with chronic stable angina, and one which discusses the use of EECP in angina patients with peripheral vascular disease. The results of these studies will be presented on Monday, March 19, 2001. Perhaps we'll hear something later today about the studies.